RE: Sadly14 Aug 2019 19:27
I did email the Conakry about holding in Polymetal but had no reply. Maybe worth a few others asking the same question and hope they reply.
I hold around 80,000 shares, average 20p, but fully accept that the company will be made in 12 months.
Imo, it’s pretty clear that BP-101 works, hence trail cut short. It will get to market in Russia within a year, in the meantime focus will shift to manufacturing in the EU entering a multi billion pound market
Plus I would imagine a partner will also come on board.
With such small float and shares in issue, and no need to dilute given the most expensive part of any drug development is behind us and paid for, the share could easily be anywhere between 50p-£1 within 8-12 months (which is nearly a 10 bagger from here) if your patient! (With plenty more upside post 12 months over £1!)
£13 mil mcap at around 13p
Look at the likes of Motif Bio et al plus always diluting shareholders
On drug to market and commercialized there is nothing stopping this being a £200mcap company with relative ease (AND we know the drug works, it’s not still R&D!).
This would give us £1.50-£2 a share
£100mil mcap is, IMO, comfortable target within 12 months if all goes to plan with Russian approvals. That’s well over £1 a share!
But it takes people to stick them away and come back in 12 months.